Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
7.74
+0.09 (1.18%)
At close: Apr 24, 2026, 4:00 PM EDT
7.89
+0.15 (1.94%)
After-hours: Apr 24, 2026, 5:27 PM EDT
Shattuck Labs Employees
Shattuck Labs had 40 employees as of December 31, 2025. The number of employees decreased by 4 or -9.09% compared to the previous year.
Employees
40
Change (1Y)
-4
Growth (1Y)
-9.09%
Revenue / Employee
$25,000
Profits / Employee
-$1,220,225
Market Cap
585.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 40 | -4 | -9.09% |
| Dec 31, 2024 | 44 | -31 | -41.33% |
| Dec 31, 2023 | 75 | -30 | -28.57% |
| Dec 31, 2022 | 105 | 20 | 23.53% |
| Dec 31, 2021 | 85 | 26 | 44.07% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Absci | 140 |
| Sutro Biopharma | 137 |
| Ocugen | 116 |
| Adlai Nortye | 109 |
| Aclaris Therapeutics | 73 |
STTK News
- 7 weeks ago - Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Shattuck Labs Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Shattuck Labs Announces Participation in Upcoming March Investor Conferences - GlobeNewsWire
- 2 months ago - Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewsWire
- 4 months ago - Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Shattuck Labs Transcript: Evercore ISI 8th Annual HealthCONx Conference - Transcripts
- 5 months ago - Shattuck Labs Transcript: Piper Sandler 37th Annual Healthcare Conference - Transcripts
- 5 months ago - Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy - Benzinga